Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Amgen Inc (NASDAQ:AMGN)

169.71
Delayed Data
As of 3:59pm ET
 -1.92 / -1.12%
Today’s Change
130.09
Today|||52-Week Range
176.85
+4.55%
Year-to-Date
FDA Approval of Amjevita Need Not Worry AbbVie Shareholders
12:07pm / GuruFocus News - Paid Partner Content
Whitman's Third Avenue Buys 3 Pharma Stocks in 3rd Quarter
Sep 27 / GuruFocus News - Paid Partner Content
Third Value Fund Avenue Buys 3 Stocks in 3rd Quarter
10:40am / GuruFocus News - Paid Partner Content
Here's Why Ligand Pharmaceuticals Inc Is Plunging Today
Sep 27 / MotleyFool.com - Paid Partner Content
Momenta to Regain Rights to Humira Biosimilar from Shire
9:52am / Zacks.com - Paid Partner Content
Stocks Hold at Highs After Clinton-Trump Debate, Oil Tumbles
Sep 27 / TheStreet.com - Paid Partner Content
Biotech Stock Roundup: Amgen's Kyprolis Disappoints, Array Up on Cancer Data
9:32am / Zacks.com - Paid Partner Content
Amgen (AMGN) Stock Slides, RBC: Clarion Trial May Have Failed Due to Design
Sep 27 / TheStreet.com - Paid Partner Content
Amgen's Multiple Myeloma Drug Kyprolis Fails in Phase III
7:54am / Zacks.com - Paid Partner Content
Amgen/UCB's BLA for Osteoporosis Drug Accepted in the U.S.
Sep 27 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close171.63
Today’s open172.22
Day’s range169.05 - 172.22
Volume3,296,980
Average volume (3 months)2,821,143
Market cap$128.4B
Dividend yield2.36%
Data as of 3:59pm ET, 09/28/2016

Growth & Valuation

Earnings growth (last year)+35.22%
Earnings growth (this year)+9.41%
Earnings growth (next 5 years)+8.30%
Revenue growth (last year)+6.49%
P/E ratio17.4
Price/Sales5.83
Price/Book4.61

Competitors

 Today’s
change
Today’s
% change
GILDGilead Sciences-0.28-0.35%
BIIBBiogen-3.98-1.27%
ILMNIllumina Inc+0.63+0.35%
NBIXNeurocrine Bioscienc...-1.94-3.64%
Data as of 4:14pm ET, 09/28/2016

Financials

Next reporting dateOctober 18, 2016
EPS forecast (this quarter)$2.80
Annual revenue (last year)$21.3B
Annual profit (last year)$6.9B
Net profit margin32.52%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Robert A. Bradway
Executive Vice President-
Operations
Esteban Santos
Corporate headquarters
Thousand Oaks, California

Forecasts

Search for Jobs